Thus, it should be considered to associate PGC-1α stimulation with inhibition of excessive NAD+ consumption as a potential strategy for counteracting NASH and other metabolic diseases. The gene discussed is PPARGC1A; the disease is metabolic dysfunction-associated steatohepatitis.